

Amendments to the Claims

Please cancel Claims 1- 27, 30 - 32, and 34 - 39. Please amend Claim 33. Please add new Claims 40 - 52. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1-32. (Cancelled)

33. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and The composition of Claim 32 wherein the compound is amonafide malate.

34-39. (Cancelled)

40. (New) The composition of Claim 33 wherein amonafide is in the monovalent form

41. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and amonafide glycolate.

42. (New) The composition of Claim 41 wherein amonafide is in the monovalent form.

43. (New) A method of treating a subject with breast cancer, comprising the step of administering to the subject an effective amount of amonafide malate or amonafide glycolate.

44. (New) The method of Claim 43 wherein amonafide is in the monovalent form.

45. (New) A method of treating a subject with colon cancer, comprising the step of administering to the subject an effective amount of amonafide malate or amonafide glycolate.

46. (New) The method of Claim 45 wherein amonafide is in the monovalent form.
47. (New) A method of treating a subject with lung cancer, comprising the step of administering to the subject an effective amount of amonafide malate or amonafide glycolate.
48. (New) The method of Claim 47 wherein amonafide is in the monovalent form.
49. (New) A method of treating a subject with prostate cancer, comprising the step of administering to the subject an effective amount of amonafide malate or amonafide glycolate.
50. (New) The method of Claim 49 wherein amonafide is in the monovalent form.
51. (New) A method of treating a subject with leukemia, comprising the step of administering to the subject an effective amount of amonafide malate or amonafide glycolate.
52. (New) The method of Claim 51 wherein amonafide is in the monovalent form.